Kite Pharma Submits IND for BCMA-Targeting CAR-T Cancer Immunotherapy

05:41 EDT 8 Aug 2017 | Genetic Engineering News

Kite Pharma said today it has submitted to the FDA an Investigational New Drug (IND) application to launch a Phase I, first-in-human trial of a CAR-T cell therapy that targets B-cell maturation antigen (BCMA) in patients with relapsed/refractory multiple myeloma. KITE-585 is designed to work through the engineering of a patient's T cells to express a chimeric antigen receptor (CAR) that targets BCMA, a protein expressed on the cell surface of multiple myelomas, then redirecting those T cells to kill cancer cells. KITE-585 contains a receptor derived from a fully human monoclonal antibody and a CD28 costimulatory domain intended for optimized T-cell expansion and function. Kite disclosed its intent to advance KITE-585 into the clinic in April, when it presented preclinical data on the CAR-T cell therapy at the American Association of Cancer Research (AACR) Annual Meeting in Washington D.C. In one study—Abstract #4979, “Development of ...

Original Article: Kite Pharma Submits IND for BCMA-Targeting CAR-T Cancer Immunotherapy


More From BioPortfolio on "Kite Pharma Submits IND for BCMA-Targeting CAR-T Cancer Immunotherapy"

Quick Search

Relevant Topics

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...